News

  • February 2021
    • We are happy to announce that we signed a collaboration agreement with another Gothenburg-based Med Tech company – OnDosis. Their solution on individualized medication delivery will be an excellent addition to our objective attention test (CPTA) when it comes to helping patients with ADHD, to get the optimal dose for their needs.

      OnDosis is addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centred around a connected handheld dosing device that delivers tailored doses of oral medicines. Together we will offer a system that represent a significant leap into the future for ADHD medication management.
      The collaboration will increase patient and customer value beyond what we can offer individually.

  • May 2020
    • Opatus CPTA 2.0 is released!
    • New App design, better robustness off-line testing, compulsory practice test, warns TestAdmins for possible misunderstood task during practice, more settings.
  • May 2018
    • Opatus participates in ”Entrepreneurship & Value Creation in Life Sciences” during #gbgtechWeek! Opatus joined CELLINK and MYoroface to give some insights in Start-up challenges and joy. Great arrangement by GU Ventures and Sahlgrenska Science Park
  • March 2018
    • First patient in to the clinical evaluation study
  • February 2018
    • The OPATest change name to Opatus CPTA.  Opa means “Grandfather” in German. Kids don’t want to take the “Grandfather-test”. We respect that.  Also we want to be more specific about what the test is about. It’s a common CPT  (Continuous Performance Test/Task) as used by psychologists since the 50’s with an added Activity measure. Thus CPT + A = Opatus CPTA
  • June 2017
    • Opatus receives support from SWELife and Region Västra Götaland, VGR, for clinical evaluation, regulatory registration and business development
  • March 2017
    • OPATest is CE marked
    • Opatus is a registered trademark
  • October 2013
    • Opatus is founded Newspaper articles often address problems with queues for assessment of neuropsychiatric disabilities such as ADHD. Can we help with technology? A request for an accessible objective test that was simpler and more affordable than existing systems, came from psychologists and doctors. We accepted the challenge .

Sign up for our newsletter

Get first hand information about our product and related subjects